Janssen Presents First Results from Dual Bispecific
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from...
Source: globenewswire.com
📰 Combination With News
Page 3 - Combination With News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Combination With. Real-time updates on events, politics, business and more.
Janssen Presents Longer-Term Talquetamab Follow-Up Data
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...
United States Castillay Leóp Region Flamande Talquetamab Monotherapy Maria Victoria Mateos Edmond Chan
Source: globenewswire.com
Sequencing The Impact: How AI Is Boosting Genomic Medicine - Healthcare
The rapid development of artificial intelligence (AI) systems will significantly impact businesses that rely on genomic data analysis for research and development of therapeutics...
Health Care Series Interpreting Complex Genomic Interpreting Genomic Non Coding Genetic Variation Genomic Data Combination With
Source: mondaq.com
Agenus Provides Corporate Update and First Quarter 2023 Financial Results
At a late-breaking presentation at ASCO-GI, botensilimab/balstilimab combination demonstrated a 63% 12-month overall survival rate in metastatic colorectal cancer patients who have failed a median... | May 9, 2023
United States New York Comunidad Autonoma De Cataluna Garo Armen Agenus Inc Society Of Gynecologic Oncology
Source: marketscreener.com
2023 Regeneron STS Scholars - Society for Science
Society for Science proudly announces the top 300 scholars in the Regeneron Science Talent Search 2021, the nation’s oldest and most prestigious science and math competition for high school seniors.
Long Island Palos Verdes Peninsula High School United States Rancho Bernardo High School Arcadia High School Massachusetts Bay
Source: societyforscience.org
Investegate |Moderna Inc Announcements | Moderna Inc: Moderna and Merck Announce mRNA Cancer Vaccine
Investegate announcements from Moderna Inc, Moderna and Merck Announce mRNA Cancer Vaccine
Source: investegate.co.uk
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...
United States Bortezomib Melphalan Douglasw Sborov Velcade Melphalan Velcade Bortezomib Melphalan Imran Khan
Source: prnewswire.com
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma - Press Release
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen Pharm
United States Bortezomib Melphalan Douglasw Sborov Velcade Melphalan Velcade Bortezomib Melphalan Imran Khan
Source: wiredprnews.com
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the final results from the randomized Phase 2 GRIFFIN study...
United States Bortezomib Melphalan Douglasw Sborov Velcade Melphalan Velcade Bortezomib Melphalan Imran Khan
Source: prnewswire.com
Final Analysis of Phase 2 GRIFFIN Study Presented for DARZALEX® (daratumumab)-based Investigational Quadruplet Regimen in Patients with Newly Diagnosed, Transplant-Eligible Multiple Myeloma
Data featured in plenary session at the 19th International Myeloma Society Annual Meeting LOS ANGELES, Aug. 27, 2022 /PRNewswire/ -- The Janssen P...
United States Bortezomib Melphalan Douglasw Sborov Velcade Melphalan Velcade Bortezomib Melphalan Imran Khan
Source: businessinsider.com